BRG1/BRM Inhibitor Targets AML Stem Cells and Exerts Superior Preclinical Efficacy Combined with BET or Menin Inhibitor

Investigators showed that FHD-286 induced differentiation and lethality in AML cells with MLL1 rearrangement or mutant NPM1, concomitantly causing perturbed chromatin accessibility and repression of c-Myc, PU.1, and CDK4/6.